Biological consequences of the BCR/ABL fusion gene in humans and mice

Journal of Clinical Pathology

Volumn 52, Issue 10, 1999, Pages 719-722

  Gordon, M Y ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CD34 ANTIGEN; CD45 ANTIGEN; METALLOPROTEINASE; MICROSOMAL AMINOPEPTIDASE; T LYMPHOCYTE RECEPTOR;

ANIMAL MODEL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COMBINED IMMUNODEFICIENCY; EDITORIAL; FUSION GENE; GENE FUSION; HEPATOSPLENOMEGALY; HUMAN; LEUKOCYTE COUNT; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 0032886857     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.10.719     Document Type: Editorial

References (45)

1. Gordon MY, Goldman JM. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br J Hacmatol 1996;95:10-20.
2. Verfaillic CM. Chronic myelogenous leukemia: from pathogenesis to therapy. J Hematother 1999;8:3-13.
3. Gordon MY, Blackett NM. Some factors determining the minimum number of cells required for successful clinical engraftment. Bone Marrow Transplant 1995;15:659-62.
4. Gordon MY, Blacken NM. Reconstruction of the hematopoietic system after stem cell transplantation. Cell Transplantation 1998;7:339-44.
5. Gordon MY, Dazzi F, Marley SB, et al. Cell biology of CML cells. Leukemia 1999;13(suppl 1):S65-71.
6. Marley SB, Lewis JL, Scott MA, et al. Evaluation of "discordant maturation" in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (CFU-GM). Br J Haematol 1996;95:299-305.
7. Amos TAS, Lewis JL, Grand FH, et al. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 1995;91:387-93.
8. Bedi A, Zenbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR ABL in chronic myeloid leukemia. Blood 1994;83:2038-44.
9. Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple cancer agents. Blood 1995;86:1148-58.
10. Roger R, Isaad C, Pallardy M, et al. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine activated killer cells. Blood 1906;87:1113-22.
11. Santucci MA, Anklesaria P, Laneuville P, et al. Expression of p210 BCR-ABL increases haematopoietic progenitor cell radiosensitivity. Int J Radiat Oncol Biol Phys 1993;26:881-9.
12. Albrecht T, Schwab R, Henkes M, et al. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 1996;94:501-7.
13. Carlo-Stella C, Dotti G, Mangoni L, et al. Selection of myeloid progenitors lacking BCR, ABL mRNA in chronic myclogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor, genesrein. Blood 1996;88:3091-100.
14. Gordon MY, Marley SB, Lewis JL, et al. Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia, but spares normal CFU-GM. J Clin Invest 1998;102:710-15.
15. Eaves CJ, Eaves AC. Stem cell kinetics. Bailliere's Clin Haematol 1997;10:233-57.
16. Clarkson BD, Strife A, Wisniewski D, et al. New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 1997;11:1404-28.
17. Thiele J, Zirbes TK, Lorenzen J, et al. Apoptosis and proliferation (PCNA labelling) in CML: a comparative immunohistological study of bone marrow biopsies following interferon and busulphan therapy. J Pathol 1997;181:316-22.
18. Gordon MY, Lewis JL, Marley SB, et al. Stromal cells negatively regulate primitive haemopoietic progenitor cell activation via a phosphatidylinosotol-anchored cell adhesion/signalling system. Br. J Hacmatol 1997;96:647-53.
19. Gordon MY, Dowding CR, Riley GP, et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342-4.
20. Verfaillie CM, McCarthy JB, McGlave P. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myclogenous leukemia: decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992;90:1232.
21. Eaves CJ, Cashman JD, Wolpe SD, et al. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci USA 1993;90:12015.
22. Nirsimloo N, Gordon MY. Progenitor cells in the blood and marrow of patients with chronic phase chronic myeloid leukaemia respond differently to macrophage inflammatory factor-1α. Leuk Res 1995;19:319-23.
23. Grand FH, Marley SB, Chase A, et al. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic mycloid leukemia patients. Leukemia 1997;11:1486-92.
24. Verfaillie CM, Bhatia R, Miller W, et al. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early chronic phase, bur not accelerated phase chronic myelogenous leukemia patients. Blood 1996;87:4770-9.
25. Brito-Bapapulle F, Bowcock SJ, Marcus RE, et al. Autografting for patients with chronic myeloid leukaemia in chronic phase:peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis. Br J Hacmatol 1989;73:76-81.
26. Talpaz M, Kantarjian HM, Kurzrock R, et al. Interferon alpha produces sustained cytogeneitc responses in chronic myeloid leukemia. Ann Intern Med 1991;114:532-8.
27. bcrabl gene of the Philadelphia chromosome. Science 1990;247:824-9.
28. Daley GQ, van Etten RA, Baltimore D. Blast crisis in a murine model of chronic myclogenous leukemia. Proc Natl Acad Sci USA 1991;88:11335-8.
29. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myclogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 1993;90:3755-9.
30. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like mycloproliferative disease in mice receiving p210 bcr/abl-transduced bone marrow. Blood 1998;92:3780-92.
31. Kelliher MA, McLaughlin J, Witte ON, et al. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87:6649-53.
32. Zhang X, Ren R. Bcr-Abl efficiently induces a mycloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998;92:3829-40.
33. Clarke SS, Chen E, Fizzotti M, et al. BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets. J Virol 1993;67:6033.
34. Hariharan IK, Harris AW, Crawford M, et al. A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 1989;9:2798.
35. bcr/abl by metallothionene promoter induced T-cell leukemia in transgenic mice. Blood 1995;85:2853-61.
36. Voncken JW, Kaarinen V, Pattengaic PK, et al. BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice. Blood 1995;86:4603-11.
37. Uckun FM. Severe combined immunodeficient mouse models of human leukemia. Blood 1996;88:1135.
38. Dick JE. Normal and leukemic stem cells assayed in SCID mice. Semin Immunol 1996;8:197-206.
39. Dazzi K, Capelli D, Hasserjian R, et al. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donarŌs disease: an in vivo model of chronic myelogenous leukemia biology. Blood 1998;92:1390-6.
40. Coggle JE, Gordon MY. Quantitative measurements on the haemopoietic systems of three strains of mice. Exp Hematol 1975;3:181-6.
41. Sawyers CL, Gishizky ML, Quan S, et al. Propagation of human blastic leukemia" in the SCID mouse. Blood 1992;79:2089-98.
42. Sirard C, Lapidot T, Vormoor J, et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase whereas leukemic SRC, are detected in blast crisis. Blood 1996;87:1539-48.
43. Wang JCY, Lapidot T, Cashman JD, et al. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998;91:2406-14.
44. Lewis ID, McDiarmid LA, Samels LM, et al. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood 1998;91:630-40.
45. Dazzi F, Boecklin F, Hasserjian R, et al. Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and differentiation pattern [abstract]. Bone Marrow Transplant 1999;23(suppl 1);S58.